- Home
- RFI vs TNGX Comparison
RFI vs TNGX Comparison
Compare RFI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- TNGX
- Stock Information
- Founded
- RFI 1992
- TNGX 2014
- Country
- RFI United States
- TNGX United States
- Employees
- RFI N/A
- TNGX N/A
- Industry
- RFI Investment Managers
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- TNGX Health Care
- Exchange
- RFI Nasdaq
- TNGX Nasdaq
- Market Cap
- RFI 323.2M
- TNGX 351.2M
- IPO Year
- RFI N/A
- TNGX N/A
- Fundamental
- Price
- RFI $11.91
- TNGX $5.88
- Analyst Decision
- RFI
- TNGX Strong Buy
- Analyst Count
- RFI 0
- TNGX 6
- Target Price
- RFI N/A
- TNGX $12.20
- AVG Volume (30 Days)
- RFI 69.8K
- TNGX 2.6M
- Earning Date
- RFI 01-01-0001
- TNGX 08-06-2025
- Dividend Yield
- RFI 8.25%
- TNGX N/A
- EPS Growth
- RFI N/A
- TNGX N/A
- EPS
- RFI N/A
- TNGX N/A
- Revenue
- RFI N/A
- TNGX $40,990,000.00
- Revenue This Year
- RFI N/A
- TNGX N/A
- Revenue Next Year
- RFI N/A
- TNGX N/A
- P/E Ratio
- RFI N/A
- TNGX N/A
- Revenue Growth
- RFI N/A
- TNGX 10.09
- 52 Week Low
- RFI $9.62
- TNGX $1.03
- 52 Week High
- RFI $12.52
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- RFI 50.83
- TNGX 73.28
- Support Level
- RFI $11.85
- TNGX $5.75
- Resistance Level
- RFI $12.08
- TNGX $6.40
- Average True Range (ATR)
- RFI 0.13
- TNGX 0.50
- MACD
- RFI -0.00
- TNGX -0.03
- Stochastic Oscillator
- RFI 58.14
- TNGX 83.80
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.